Your browser doesn't support javascript.
loading
Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants.
Jethava, Yogesh S; Mitchell, Alan; Epstein, Joshua; Zangari, Maurizio; Yaccoby, Shmuel; Tian, Erming; Waheed, Sarah; Khan, Rashid; Papanikolaou, Xenofon; Grazziutti, Monica; Cottler-Fox, Michele; Petty, Nathan; Steward, Douglas; Panozzo, Susan; Bailey, Clyde; Hoering, Antje; Crowley, John; Sawyer, Jeffrey; Morgan, Gareth; Barlogie, Bart; van Rhee, Frits.
Afiliação
  • Jethava YS; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
  • Mitchell A; Cancer Research and Biostatistics, Seattle, Washington.
  • Epstein J; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
  • Zangari M; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
  • Yaccoby S; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
  • Tian E; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
  • Waheed S; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
  • Khan R; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
  • Papanikolaou X; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
  • Grazziutti M; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
  • Cottler-Fox M; Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
  • Petty N; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
  • Steward D; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
  • Panozzo S; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
  • Bailey C; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
  • Hoering A; Cancer Research and Biostatistics, Seattle, Washington.
  • Crowley J; Cancer Research and Biostatistics, Seattle, Washington.
  • Sawyer J; Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
  • Morgan G; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
  • Barlogie B; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
  • van Rhee F; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas. vanrheefrits@uams.edu.
Clin Cancer Res ; 23(11): 2665-2672, 2017 Jun 01.
Article em En | MEDLINE | ID: mdl-27810902
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Talidomida / Bortezomib / Melfalan / Mieloma Múltiplo Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Talidomida / Bortezomib / Melfalan / Mieloma Múltiplo Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article